Acumen Wealth Advisors LLC increased its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 1,582.0% i

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced tod

Gilead Sciences and Merck said on Tuesday their experimental once-weekly HIV pill kept the virus sup

FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest na

Andra AP fonden decreased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 53.9% during the u

Dimensional Fund Advisors LP reduced its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 12.7% i

Boston Common Asset Management LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:

Allspring Global Investments Holdings LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ: G

In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% sh

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exp

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $24.25, against a Wall Street consensus price tar

Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling particip

Gilead is seeing success with new oncology and inflammation therapies. The drugmaker went on an acqu

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72%

You don't need to predict a recession to prepare your portfolio. These two stocks can help.

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight

On July 07, 2026, Gilead Sciences Inc (GILD) shares rose 5.2% today, with the current price at $136.

On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform

Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lo

Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and str

HSBC upgraded Gilead Sciences Inc. (NASDAQ:GILD) on Monday, citing that the consensus is ‘too pessim

HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight

Wall Street analysts upgraded several top stocks, including T-Mobile, US Bancorp, Gilead Sciences, T

HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and raises t

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.07% on an annu

FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expandin

U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembr

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma

CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company

Supreme Court lets Medicare drug price negotiations continue, rejecting pharma industry challenges t

Nasdaq jumps 1.6% to record highs Friday as semiconductor rally and stronger-than-expected April pay

Tempus AI (TEM) Q1 results: Revenue up 36.1% to $348.1M, beating estimates. TEM raises 2026 outlook

Gilead expands Tempus AI deal and licenses Kymera's KT-200, advancing oncology pipeline with dat

KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise

After three straight rebound sessions, the software selloff resumed Wednesday, with the iShares Tech

https://www.bloomberg.com/news/articles/2025-08-04/south-africa-gates-step-in-after-us-defunds-hiv-r

Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings